Dr Christine Carrington
Dr Christine Carrington is a Senior Consultant Pharmacist for Cancer Services and Deputy Director of Pharmacy at the Princess Alexandra Hospital in Brisbane. She has over 30 years’ experience working as a pharmacist in cancer at a clinical, service and research level in Australia and overseas. Christine lectures at the University of Queensland on topics related to cancer and supervises undergraduate and postgraduate pharmacy students. She is an elected member of the Clinical Oncology Society of Australia (COSA) board, having sat on the board since 2013. Christine was awarded the Australian Clinical Pharmacist award in 2015 by the Society of Hospital Pharmacists of Australia (SHPA) in recognition of outstanding contributions in clinical pharmacy practice in cancer. She regularly conducts and collaborates in research relating to cancer therapy and clinical pharmacy practice. Her research includes investigating the impact of the clinical pharmacist on the medication management of cancer patients, the influence of the pharmacist on cancer patients understanding and beliefs around their medication and the management of chemotherapy induced nausea and vomiting. Christine’s published work includes articles on oral chemotherapy, targeted cancer therapy, pharmacist competency and medication safety. She regularly presents at conferences, seminars and runs workshops on topics relating to cancer therapy and is an advocate for educational opportunities for all health care disciplines. Christine has a keen interest in safe medication practices in cancer therapy across the multidisciplinary setting. She has recently led the multidisciplinary working group for the review and development of the COSA national guidelines for the ‘Safe Prescribing, Dispensing and Administration of Cancer therapy’ which have been published on the Cancer Council Wiki platform. Her clinical interests include chemotherapy-induced nausea and vomiting, the role of immunotherapy in the treatment of cancer and the therapeutic management of haematological malignancies, breast cancer and melanoma.